JP2026021299A5 - - Google Patents
Info
- Publication number
- JP2026021299A5 JP2026021299A5 JP2025159746A JP2025159746A JP2026021299A5 JP 2026021299 A5 JP2026021299 A5 JP 2026021299A5 JP 2025159746 A JP2025159746 A JP 2025159746A JP 2025159746 A JP2025159746 A JP 2025159746A JP 2026021299 A5 JP2026021299 A5 JP 2026021299A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- cell
- tcr
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475329P | 2017-03-23 | 2017-03-23 | |
| US62/475,329 | 2017-03-23 | ||
| DE102017106305.6A DE102017106305A1 (de) | 2017-03-23 | 2017-03-23 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| DE102017106305.6 | 2017-03-23 | ||
| JP2019552175A JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023044130A Division JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026021299A JP2026021299A (ja) | 2026-02-10 |
| JP2026021299A5 true JP2026021299A5 (https=) | 2026-03-11 |
Family
ID=61899213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552175A Withdrawn JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A Active JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2025159746A Pending JP2026021299A (ja) | 2017-03-23 | 2025-09-26 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552175A Withdrawn JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A Active JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11236145B2 (https=) |
| EP (2) | EP3600409B1 (https=) |
| JP (3) | JP2020511152A (https=) |
| KR (2) | KR20190132655A (https=) |
| CN (2) | CN118852404A (https=) |
| AU (2) | AU2018240501B2 (https=) |
| BR (1) | BR112019019523A2 (https=) |
| CA (1) | CA3056493A1 (https=) |
| CL (1) | CL2019002645A1 (https=) |
| CO (1) | CO2019011688A2 (https=) |
| CR (1) | CR20190482A (https=) |
| DK (1) | DK3600409T3 (https=) |
| ES (1) | ES2986840T3 (https=) |
| FI (1) | FI3600409T3 (https=) |
| HR (1) | HRP20241228T1 (https=) |
| HU (1) | HUE068640T2 (https=) |
| IL (2) | IL269578B2 (https=) |
| LT (1) | LT3600409T (https=) |
| MA (1) | MA47932B1 (https=) |
| MD (1) | MD3600409T2 (https=) |
| MX (2) | MX2019011260A (https=) |
| MY (1) | MY199084A (https=) |
| PE (1) | PE20191493A1 (https=) |
| PH (1) | PH12019502151A1 (https=) |
| PL (1) | PL3600409T3 (https=) |
| PT (1) | PT3600409T (https=) |
| RS (1) | RS65924B1 (https=) |
| SG (1) | SG11201908023YA (https=) |
| SI (1) | SI3600409T1 (https=) |
| SM (1) | SMT202400351T1 (https=) |
| TW (1) | TWI799922B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| WO2020172332A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EP3965818A4 (en) * | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| EP4061827A1 (en) * | 2019-11-18 | 2022-09-28 | BioNTech SE | Prame tcr receptors and uses thereof |
| IL294988A (en) * | 2020-01-24 | 2022-09-01 | Regeneron Pharma | Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| CN113789304B (zh) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | 高亲和力tcr及其应用 |
| CN113817044B (zh) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T细胞受体、相关工程化细胞及其应用 |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| CN119546328A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115073584B (zh) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | 一种特异性识别prame抗原肽的tcr及其应用 |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| KR20140039318A (ko) | 2011-06-28 | 2014-04-01 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자 |
| RU2578009C2 (ru) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP2018510627A (ja) | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| TW201702272A (zh) | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| CN106084036A (zh) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | 识别prame抗原短肽的t细胞受体 |
| CN106478809B (zh) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的tcr |
| CN106519019B (zh) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
| CN106831978B (zh) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
| CN106699874B (zh) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
| EP3472208B9 (en) | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | T cell receptors and uses thereof |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 LT LTEPPCT/EP2018/057482T patent/LT3600409T/lt unknown
- 2018-03-23 CR CR20190482A patent/CR20190482A/es unknown
- 2018-03-23 MD MDE20200121T patent/MD3600409T2/ro unknown
- 2018-03-23 IL IL269578A patent/IL269578B2/en unknown
- 2018-03-23 ES ES18715559T patent/ES2986840T3/es active Active
- 2018-03-23 MY MYPI2019005257A patent/MY199084A/en unknown
- 2018-03-23 MA MA47932A patent/MA47932B1/fr unknown
- 2018-03-23 CN CN202410804111.1A patent/CN118852404A/zh active Pending
- 2018-03-23 PL PL18715559.3T patent/PL3600409T3/pl unknown
- 2018-03-23 HR HRP20241228TT patent/HRP20241228T1/hr unknown
- 2018-03-23 FI FIEP18715559.3T patent/FI3600409T3/fi active
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/ko not_active Ceased
- 2018-03-23 SM SM20240351T patent/SMT202400351T1/it unknown
- 2018-03-23 CN CN201880019206.5A patent/CN110494160B/zh active Active
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/ja not_active Withdrawn
- 2018-03-23 AU AU2018240501A patent/AU2018240501B2/en active Active
- 2018-03-23 HU HUE18715559A patent/HUE068640T2/hu unknown
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/es unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/zh active
- 2018-03-23 EP EP18715559.3A patent/EP3600409B1/en active Active
- 2018-03-23 IL IL310552A patent/IL310552B2/en unknown
- 2018-03-23 RS RS20240992A patent/RS65924B1/sr unknown
- 2018-03-23 SI SI201831150T patent/SI3600409T1/sl unknown
- 2018-03-23 KR KR1020247033132A patent/KR20240151870A/ko active Pending
- 2018-03-23 DK DK18715559.3T patent/DK3600409T3/da active
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
- 2018-03-23 EP EP24194122.8A patent/EP4450087A3/en active Pending
- 2018-03-23 PT PT187155593T patent/PT3600409T/pt unknown
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/es unknown
- 2018-03-23 BR BR112019019523-8A patent/BR112019019523A2/pt unknown
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/es unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/es unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/es unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP7787119B2/ja active Active
-
2025
- 2025-03-24 AU AU2025202086A patent/AU2025202086A1/en active Pending
- 2025-09-26 JP JP2025159746A patent/JP2026021299A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026021299A5 (https=) | ||
| JP2019528061A5 (https=) | ||
| JP2023139070A5 (https=) | ||
| ES2373652T3 (es) | Anticuerpo citotóxico contra un péptido c-terminal de gpc-3. | |
| ES2374845T3 (es) | Tratamiento de cáncer con anticuerpos anti-il-1. | |
| JP2019511222A5 (https=) | ||
| JP2017186337A5 (https=) | ||
| JP6070191B2 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| JP2021137036A5 (https=) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JPWO2021155380A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| CN103717238A (zh) | 胰癌的治疗和/或预防用药物组合物 | |
| JP2016505513A5 (https=) | ||
| JP2020513745A5 (https=) | ||
| JP2020511414A5 (https=) | ||
| JP2019534246A5 (https=) | ||
| JP2020512019A5 (https=) | ||
| JP2010531140A5 (https=) | ||
| RU2020127887A (ru) | Полипептиды транспозазы и их применение | |
| HUP0401695A2 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
| JP2021530971A5 (https=) | ||
| KR20210143804A (ko) | 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t) | |
| JP2023089103A5 (https=) | ||
| CN109810995A (zh) | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |